2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 128 filers reported holding 2SEVENTY BIO INC in Q4 2021. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $89 | -42.2% | 22,600 | +50.1% | 0.00% | -50.0% |
Q1 2023 | $154 | +21.3% | 15,056 | +11.3% | 0.00% | 0.0% |
Q4 2022 | $127 | -99.9% | 13,533 | +16.1% | 0.00% | 0.0% |
Q3 2022 | $170,000 | -55.4% | 11,652 | -59.6% | 0.00% | -50.0% |
Q2 2022 | $381,000 | +35.6% | 28,828 | +163.4% | 0.00% | +100.0% |
Q4 2021 | $281,000 | – | 10,946 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Newtyn Management, LLC | 1,587,805 | $27,088,000 | 6.49% |
CHI Advisors LLC | 819,672 | $13,984,000 | 5.95% |
Madison Avenue Partners, LP | 896,972 | $15,302,342,000 | 2.86% |
Bain Capital Life Sciences Investors, LLC | 1,408,901 | $24,036,000 | 2.33% |
EcoR1 Capital, LLC | 3,495,943 | $59,641,000 | 1.87% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $5,118,000 | 1.02% |
CVI Holdings, LLC | 819,672 | $13,984,000 | 0.92% |
ARMISTICE CAPITAL, LLC | 2,000,000 | $34,120,000 | 0.66% |
Altium Capital Management LP | 115,000 | $1,962,000 | 0.66% |
Casdin Capital, LLC | 614,754 | $10,488,000 | 0.47% |